Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)

NCT02302989 is registered in ClinicalTrials.gov with Leonard Feiner, MD, PhD as lead sponsor.

NCT NCT02302989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02302989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)
Lead sponsor
Leonard Feiner, MD, PhD
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2015
Completion date
July 31, 2018
Enrollment
4 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration